

Key Indices Update

Indices	Close	Change (%)
Nifty	24,683.90	1.05
Sensex	81,186.44	لا 1.06
Midcap	56,182.65	וב1.62
Smallcap	17,483.00	0.94 ע

Trend Strength Indicator


Nifty 50 Stocks above	NSE Advance /
200 EMA	Decline
31	915 /1974

Key Data

Data	Current	Previous
Dow Jones	42,621.5	42,776.5
U.S. Dollar Index	99.92	100.32
Brent Crude (USD/BBL)	66.40	65.52
US 10Y Bond Yield (%)	4.50	4.45
India 10Y Bond Yield (%)	6.26	6.26

Sectoral Data

Sector	Close	Change (%)
BANKNIFTY	54926.90	4 8.0
NIFTYAUTO	23589.15	ע1.93
NIFTYENERG	35454.40	0.66
NIFTYFINSR	28110.15	ו.21
NIFTYFMCG	56309.10	1.14
NIFTYIT	37366.55	ل ا0.30
NIFTYMEDIA	1651.25	ו 1.22
NIFTYMETAL	9182.70	ע0.30
NIFTYPHARM	21476.15	וא 1.22
NIFTYREALT	926.15	0.76



Market Radiance

: Read : Repeat

Top News

- Infosys has been recognized as a Leader in Modern Application Development Services by Forrester. The company received the top score in the current offering category and the highest scores possible in 14 out of 25 criteria. Infosys excels in agile development, platform engineering, and collaborations with partners.
- + United Breweries is expanding its production capacity in Andhra Pradesh through a leasing arrangement with Ilios Breweries. This move, following excise approval, aims to meet rising consumer demand for Kingfisher beer and enhance distribution efficiency

Technical

Refer Page 03-04


- Nifty edged lower after two days of consolidation, slipping over a percent amid mixed global cues.
- + Following a flat start, **profit-taking in heavyweight stocks across sectors dragged the Nifty index down,** which eventually settled at 24,683.90.
- + All the key sectoral indices moved in tandem with the broader decline, with auto, pharma, and FMCG emerging as the top losers.
- While the breach of the 24,800 mark in Nifty has dampened near-term momentum, the short-term trend remains positive as long as the index holds above the 24,400 level decisively.
- + In the meantime, we advise **traders to avoid aggressive long positions and focus on sectors or themes** that are showing relative strength.
- + Stock of the day GAIL



Market Radiance

Fundamental

Top News








Technical

Profit taking may extend. Limit aggressive positions.

NIFTY	SI	S2	RI	R2	
24683.90 뇌 261.55 (1.05%)	24600	24400	24850	25000	





- Nifty edged lower after two days of consolidation, slipping over a percent amid mixed global cues.
- Following a flat start, profit-taking in heavyweight stocks across sectors dragged the Nifty index down, which eventually settled at 24,683.90.
- All the key sectoral indices moved in tandem with the broader decline, with auto, pharma, and FMCG emerging as the top losers.
- In the meantime, we advise traders to avoid aggressive long positions and focus on sectors or themes that are showing relative strength.

BANKNIFTY	S1	S2	R1	R2
54877.35 뇌 543.35 (0.98%)	54500	54100	55200	55600



- The banking index faced rejection at higher level again, triggering selling pressure which led to a percent cut.
- The weakness was widespread wherein
 Federalbnk, Hdfcbank, Bankbaroda lost the most.
- The Banknifty has been consolidating sideways for nearly a month, struggling to breach the 55,700-56,100 resistance zone.
- Meanwhile, on the flip side, 54,400-54,200
 range has provided strong support.
- + Given the situation, it's advisable to wait for a decisive breakout or breakdown before planning the next directional trade.



Market Radiance

Technical

Stock of the day	Recom.	CMP (₹)	Range*	SL	Target
GAIL	BUY	191.10	190-192	185	203

Technical Chart : Daily



- + GAIL has been inching higher post a **breakout** from its corrective phase with noticeable rise in volumes.
- + The stock is **finding renewed buying interest** as it surpasses the cluster of important averages.
- The price and volume action suggest continuation of positive momentum in the stock.
- + Traders can consider longs in the mentioned range.

	Name	Price	Price %
	CCL	839.80	10.77 7
ap	ZENSARTECH	837.60	6.397
Midcap	RBA	85.44	4.397
-	EASEMYTRIP	11.52	4.71×
	QUESS	338.75	9.24

Name	Price	Price %	-
COALINDIA	408.95	1.557	Rang Bi
BHARTIARTL	1809.70	0.47ש	nge B Break
LUPIN	1969.50	ע2.96	ye Breakou reakdown
-	-	-	/n /n
-	-	-	

Name	Price	Price %	Тор
TITAGARH	890.05	ב(5.01	р Б
ETERNAL	228.00	لا4.21	F&O
HFCL	86.10	4.12	5
NBCC	111.30	גפ <u>.</u> 3	Losers
ASTRAL	1363.00	2.95 کا	Ľ

Name	Price	Price %	
BANDHANBNK	165.44	3.00	Bearish
ETERNAL	228.00	4.21	
LUPIN	1969.50	2.96	Charts
RECLTD	394.60	3.06 ۷	rts
TITAGARH	890.05	ב(5.01	

Momentum Stocks Midcan

Bullish Charts

Name	Price	Price %
DLF	757.50	2.697
COALINDIA	408.95	1.557
TATASTEEL	159.59	1.287
CESC	174.75	1.197
HINDALCO	666.00	1.167

Name	Price	Price %
CESC	174.75	1.197
DLF	757.50	2.697
GAIL	191.40	1.017
ONGC	249.05	1.007
UNIONBANK	138.45	1.087



Market Radiance Click : Read : Repeat

Research Team

Name	Email ID
Ajit Mishra	ajit.mishra@religare.com
Abhijeet Banerjee	abhijeet.banerjee@religare.com
Gaurav Sharma	gauravsharma2@religare.com
Ashwani Harit	ashwani.harit@religare.com
Divya Parmar	divya.parmar@religare.com
Vinay Kalani	vinay.kalani1@religare.com
Rajan Gupta	rajan.gupta1@religare.com



Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: https://www.religareonline.com/disclaimer

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/ are as under:

Statements on ownership and material conflicts of interest, compensation- Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	atement		Answer	
		Yes	No	
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No	
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No	
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No	
	I/we have received any compensation from the subject company in the past twelve months?		No	
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No	
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No	
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No	
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No	
	I/we have served as an officer, director or employee of the subject company?		No	
	I/we have been engaged in market making activity for the subject company?		No	

Market Radiance

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results



